MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2215/cjn.06141108

Медицинская библиотека · Clinical journal of the American Society of Nephrology : CJASN · 2009

Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl.

Sprague Stuart M, Evenepoel Pieter, Curzi Mario P, González Maria Teresa, Husserl Fred E, Kopyt Nelson, Sterling Lulu Ren, Mix Chris, Wong Gordon

Контролируемое клиническое исследованиеСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND &

OBJECTIVES

Chronic kidney disease (CKD) is commonly complicated by secondary hyperparathyroidism (SHPT), leading to increased risk of morbidity and mortality. SHPT is a progressive disease often requiring long-term therapy to control parathyroid hormone (PTH) and mineral imbalances. Vitamin D sterols and phosphate binders, used as traditional therapies to lower PTH and phosphorus, may provide inadequate long-term control for many dialysis patients. Cinacalcet, by simultaneously lowering PTH, calcium, phosphorus, and calcium-phosphorus levels, may maintain PTH and mineral balance in these individuals. However, as with traditional therapies, long-term data are limited. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENT: Dialysis subjects from at least one of five lead-in studies (double-blind placebo-controlled, including one extension trial) completing up to 52 wk of either cinacalcet or placebo were eligible for this open-label extension study, including an 8-wk dose titration (initiated at 30 mg/d), followed by 24-wk maintenance and up to 132 wk of follow-up. Final efficacy analysis was at week 180.

RESULTS

Three hundred thirty-four of 589 enrolled subjects received cinacalcet from the beginning of the lead-in study. Weekly median PTH values were < or =300 pg/ml (weeks 16 through 180) and median CaxP values were < or =55 mg(2)/dl(2) (weeks 4 through 180). Similar results were exhibited in the 255 subjects who initially received placebo. Among the patients exposed to cinacalcet from the beginning of the lead-in study, 3% of subjects exhibited treatment-related serious adverse events.

CONCLUSIONS

Cinacalcet effectively maintained PTH, Ca and P reductions in dialysis subjects for up to 180 wk.

Для цитирования: Sprague Stuart M, Evenepoel Pieter, Curzi Mario P, González Maria Teresa, Husserl Fred E, Kopyt Nelson, Sterling Lulu Ren, Mix Chris, Wong Gordon. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl.. Clinical journal of the American Society of Nephrology : CJASN. 2009. DOI: 10.2215/cjn.06141108.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.